Sickle cell-haemoglobin E (HbSE) compound heterozygosity: A clinical and haematological study

H. H M Knox-Macaulay, M. M. Ahmed, D. Gravell, S. Al-Kindi, A. Ganesh

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The paucity of clinical reports in the world literature suggests that, as a disease entity, haemoglobin SE compound heterozygosity is of negligible importance. In view of the significant community prevalence of this haemoglobinopathy in the Sultanate of Oman where it is the second most prevalent sickling disorder, a hospital study of 12 SE compound heterozygotes from six unrelated Arab families was undertaken to determine their clinico-haematological features. Our findings were compared with those reviewed in the literature. Clinical and haematological evaluation was carried out by conventional methods including chromatographic haemoglobin analysis. At least 50% of those studied were asymptomatic throughout the study period but sickling-related complications occurred in the rest and included the acute chest syndrome (1/12), severe vaso-occlusive skeletal pain (2/12), frontal bossing (1/12) possibly indicative of significant chronic haemolysis and recurrent infections of the urinary tract (1/12). Steady-state haemoglobin levels fell within the reference range while MCV and MCH values were, as expected, reduced in most cases; nevertheless, concomitant inheritance of α-thalassaemia trait was also likely. Red cell morphology was striking by the absence or rarity of pseudo-sickled cells in the blood films of many patients during the steady state and in crises. Bearing in mind the prevalence of 0.05% of SE compound heterozygosity in Oman, the findings in this single study of the largest number of SE patients and their relatives confirm the predominantly asymptomatic nature of this sickling disorder in individuals in the community at large. HbF levels do not appear to explain the heterogeneous nature of this haemoglobinopathy. Correlation of the variable clinical and haematological features of SE cases with their α-globin gene status and β-cluster haplotypes (linked to the βs- and βe-genes) merits a separate investigation, which is being currently organized.

Original languageEnglish
Pages (from-to)292-301
Number of pages10
JournalInternational Journal of Laboratory Hematology
Volume29
Issue number4
DOIs
Publication statusPublished - Aug 2007

Fingerprint

Hemoglobin E
Sickle Hemoglobin
Oman
Hemoglobinopathies
Hemoglobins
Genes
Acute Chest Syndrome
Thalassemia
Globins
Motion Pictures
Heterozygote
Multigene Family
Hemolysis
Urinary Tract Infections
Haplotypes
Chromatography
Blood Cells
Reference Values
Blood
Sand

Keywords

  • Compound heterozygotes
  • Haemoglobinopathy
  • SE
  • Sickling

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical
  • Hematology

Cite this

Sickle cell-haemoglobin E (HbSE) compound heterozygosity : A clinical and haematological study. / Knox-Macaulay, H. H M; Ahmed, M. M.; Gravell, D.; Al-Kindi, S.; Ganesh, A.

In: International Journal of Laboratory Hematology, Vol. 29, No. 4, 08.2007, p. 292-301.

Research output: Contribution to journalArticle

@article{a6898b9c7245498c92894464f23e8b39,
title = "Sickle cell-haemoglobin E (HbSE) compound heterozygosity: A clinical and haematological study",
abstract = "The paucity of clinical reports in the world literature suggests that, as a disease entity, haemoglobin SE compound heterozygosity is of negligible importance. In view of the significant community prevalence of this haemoglobinopathy in the Sultanate of Oman where it is the second most prevalent sickling disorder, a hospital study of 12 SE compound heterozygotes from six unrelated Arab families was undertaken to determine their clinico-haematological features. Our findings were compared with those reviewed in the literature. Clinical and haematological evaluation was carried out by conventional methods including chromatographic haemoglobin analysis. At least 50{\%} of those studied were asymptomatic throughout the study period but sickling-related complications occurred in the rest and included the acute chest syndrome (1/12), severe vaso-occlusive skeletal pain (2/12), frontal bossing (1/12) possibly indicative of significant chronic haemolysis and recurrent infections of the urinary tract (1/12). Steady-state haemoglobin levels fell within the reference range while MCV and MCH values were, as expected, reduced in most cases; nevertheless, concomitant inheritance of α-thalassaemia trait was also likely. Red cell morphology was striking by the absence or rarity of pseudo-sickled cells in the blood films of many patients during the steady state and in crises. Bearing in mind the prevalence of 0.05{\%} of SE compound heterozygosity in Oman, the findings in this single study of the largest number of SE patients and their relatives confirm the predominantly asymptomatic nature of this sickling disorder in individuals in the community at large. HbF levels do not appear to explain the heterogeneous nature of this haemoglobinopathy. Correlation of the variable clinical and haematological features of SE cases with their α-globin gene status and β-cluster haplotypes (linked to the βs- and βe-genes) merits a separate investigation, which is being currently organized.",
keywords = "Compound heterozygotes, Haemoglobinopathy, SE, Sickling",
author = "Knox-Macaulay, {H. H M} and Ahmed, {M. M.} and D. Gravell and S. Al-Kindi and A. Ganesh",
year = "2007",
month = "8",
doi = "10.1111/j.1365-2257.2006.00886.x",
language = "English",
volume = "29",
pages = "292--301",
journal = "International Journal of Laboratory Hematology",
issn = "1751-5521",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Sickle cell-haemoglobin E (HbSE) compound heterozygosity

T2 - A clinical and haematological study

AU - Knox-Macaulay, H. H M

AU - Ahmed, M. M.

AU - Gravell, D.

AU - Al-Kindi, S.

AU - Ganesh, A.

PY - 2007/8

Y1 - 2007/8

N2 - The paucity of clinical reports in the world literature suggests that, as a disease entity, haemoglobin SE compound heterozygosity is of negligible importance. In view of the significant community prevalence of this haemoglobinopathy in the Sultanate of Oman where it is the second most prevalent sickling disorder, a hospital study of 12 SE compound heterozygotes from six unrelated Arab families was undertaken to determine their clinico-haematological features. Our findings were compared with those reviewed in the literature. Clinical and haematological evaluation was carried out by conventional methods including chromatographic haemoglobin analysis. At least 50% of those studied were asymptomatic throughout the study period but sickling-related complications occurred in the rest and included the acute chest syndrome (1/12), severe vaso-occlusive skeletal pain (2/12), frontal bossing (1/12) possibly indicative of significant chronic haemolysis and recurrent infections of the urinary tract (1/12). Steady-state haemoglobin levels fell within the reference range while MCV and MCH values were, as expected, reduced in most cases; nevertheless, concomitant inheritance of α-thalassaemia trait was also likely. Red cell morphology was striking by the absence or rarity of pseudo-sickled cells in the blood films of many patients during the steady state and in crises. Bearing in mind the prevalence of 0.05% of SE compound heterozygosity in Oman, the findings in this single study of the largest number of SE patients and their relatives confirm the predominantly asymptomatic nature of this sickling disorder in individuals in the community at large. HbF levels do not appear to explain the heterogeneous nature of this haemoglobinopathy. Correlation of the variable clinical and haematological features of SE cases with their α-globin gene status and β-cluster haplotypes (linked to the βs- and βe-genes) merits a separate investigation, which is being currently organized.

AB - The paucity of clinical reports in the world literature suggests that, as a disease entity, haemoglobin SE compound heterozygosity is of negligible importance. In view of the significant community prevalence of this haemoglobinopathy in the Sultanate of Oman where it is the second most prevalent sickling disorder, a hospital study of 12 SE compound heterozygotes from six unrelated Arab families was undertaken to determine their clinico-haematological features. Our findings were compared with those reviewed in the literature. Clinical and haematological evaluation was carried out by conventional methods including chromatographic haemoglobin analysis. At least 50% of those studied were asymptomatic throughout the study period but sickling-related complications occurred in the rest and included the acute chest syndrome (1/12), severe vaso-occlusive skeletal pain (2/12), frontal bossing (1/12) possibly indicative of significant chronic haemolysis and recurrent infections of the urinary tract (1/12). Steady-state haemoglobin levels fell within the reference range while MCV and MCH values were, as expected, reduced in most cases; nevertheless, concomitant inheritance of α-thalassaemia trait was also likely. Red cell morphology was striking by the absence or rarity of pseudo-sickled cells in the blood films of many patients during the steady state and in crises. Bearing in mind the prevalence of 0.05% of SE compound heterozygosity in Oman, the findings in this single study of the largest number of SE patients and their relatives confirm the predominantly asymptomatic nature of this sickling disorder in individuals in the community at large. HbF levels do not appear to explain the heterogeneous nature of this haemoglobinopathy. Correlation of the variable clinical and haematological features of SE cases with their α-globin gene status and β-cluster haplotypes (linked to the βs- and βe-genes) merits a separate investigation, which is being currently organized.

KW - Compound heterozygotes

KW - Haemoglobinopathy

KW - SE

KW - Sickling

UR - http://www.scopus.com/inward/record.url?scp=34447269181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447269181&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2257.2006.00886.x

DO - 10.1111/j.1365-2257.2006.00886.x

M3 - Article

C2 - 17617080

AN - SCOPUS:34447269181

VL - 29

SP - 292

EP - 301

JO - International Journal of Laboratory Hematology

JF - International Journal of Laboratory Hematology

SN - 1751-5521

IS - 4

ER -